Oncology Institute (NASDAQ:TOI) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Oncology Institute (NASDAQ:TOI) announced its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02), FiscalAI reports. The firm had revenue of $136.56 million during the quarter, compared to analysts’ expectations of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 14.26%. Oncology Institute updated its FY 2025 guidance to EPS.

Oncology Institute Price Performance

TOI stock traded up $0.85 during mid-day trading on Friday, hitting $3.93. 6,224,506 shares of the stock were exchanged, compared to its average volume of 1,609,297. The business has a fifty day moving average price of $3.74 and a 200 day moving average price of $3.32. The stock has a market capitalization of $367.01 million, a price-to-earnings ratio of -5.79 and a beta of 0.07. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $4.88. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.62 and a quick ratio of 1.37.

Insider Activity at Oncology Institute

In other Oncology Institute news, Director Growth I. L.P. M33 sold 6,018,168 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the completion of the sale, the director directly owned 7,932,389 shares of the company’s stock, valued at $24,511,082.01. The trade was a 43.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in Oncology Institute during the 2nd quarter worth approximately $3,028,000. Geode Capital Management LLC boosted its holdings in Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after acquiring an additional 893,696 shares in the last quarter. UBS Group AG boosted its stake in shares of Oncology Institute by 151.2% during the 3rd quarter. UBS Group AG now owns 1,055,862 shares of the company’s stock valued at $3,685,000 after purchasing an additional 635,489 shares in the last quarter. Balyasny Asset Management L.P. lifted its holdings in Oncology Institute by 17.3% in the second quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock worth $5,163,000 after buying an additional 371,005 shares during the period. Finally, Massar Capital Management LP raised its position in shares of Oncology Institute by 300.0% in the 2nd quarter. Massar Capital Management LP now owns 400,000 shares of the company’s stock worth $820,000 after acquiring an additional 300,000 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Noble Financial started coverage on shares of Oncology Institute in a research report on Wednesday, July 23rd. They issued an “outperform” rating and a $8.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of Oncology Institute in a report on Tuesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Oncology Institute currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.